The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia results from stable isotope kinetic study in vivo
Hayato Tada; Masa-Aki Kawashiri; Katsunori Ikewaki; Yoshio Terao; Tohru Noguchi; Chiaki Nakanishi; Masayuki Tsuchida; Mutsuko Takata; Kenji Miwa; Tetsuo Konno; et al. (Profiled Authors: MASAKAZU YAMAGISHI; TETSUO KONNO; AKIHIRO INAZU; JUNJI KOBAYASHI; HIROSHI MABUCHI; ATSUSHI NOHARA; TORU NOGUCHI; MASAAKI KAWASHIRI; KENSHI HAYASHI; HAYATO TADA)
Circulation: Cardiovascular Genetics. 2012;5(1):35-41.Abstract
Background-Autosomal recessive hypercholesterolemia (ARH) exhibits different responsiveness to statins compared with that in homozygous familial hypercholesterolemia (FH). However, few data exist regarding lipoprotein metabolism of ARH. Therefore, we aimed to clarify lipoprotein metabolism, especially the remnant lipoprotein fractions of ARH before and after statin therapy. Methods and Results-We performed a lipoprotein kinetic study in an ARH patient and 7 normal control subjects, using stable isotope methodology (10 mg/kg of [2H3]-leucine). These studies were performed at baseline and after the 20 mg daily dose of atorvastatin. Tracer/tracee ratio of apolipoprotein B (apoB) was determined by gas chromatography/mass spectrometry and fractional catabolic rates (FCR) were determined by multicompartmental modeling, including remnant lipoprotein fractions. FCR of low-density lipoprotein (LDL) apoB of ARH was significantly lower than those of control subjects (0.109 versus 0.450=0.122 1/day). In contrast, the direct removal of very-low-density lipoprotein remnant was significantly greater in ARH than those in control subjects (47.5 versus 2=2%). Interestingly, FCR of LDL apoB in ARH dramatically increased to 0.464 1/day, accompanying reduction of LDL cholesterol levels from 8.63 to 4.22 mmol/L after treatment with atorvastatin of 20 mg/d for 3 months. Conclusions-These results demonstrate that ARH exhibits decreased LDL clearance associated with decreased FCR of LDL apoB and increased clearance for very-low-density lipoprotein remnant. We suggest that increased clearance of remnant lipoprotein fractions could contribute to the great responsiveness to statins, providing new insights into the lipoprotein metabolism of ARH and the novel pharmacological target for LDLRAP1. © 2011 American Heart Association, Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Hitoshi Ando; Koh-Ichi Sugimoto; Hayato Yanagihara; Shuichi Tsuruoka; Tetsuo Saito; Toshinari Takamura; Shuichi Kaneko; Akio FujimuraClinical and Experimental Pharmacology and Physiology. 2008;35(9):1012-1017.
H. Mabuchi; H. Fujita; I. Michishita; M. Takada; K. Kajinami; J. Koizumi; R. Takeda; T. Takagoshi; T. Wakasugi; K. Ueda; et al.
Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresisAtherosclerosis. 1988;72(2-3):183-188.
T. Teramoto; Y. Goto; K. Kurokawa; H. Nakamura; S. Yoshida; Y. Saito; N. Nakaya; H. Itakura; F. Takaku; et al.American Journal of Cardiology. 1995;76(2):33A-36A.
Appears in this Document